Who is sponsoring NCT03679468?

NCT03679468 is sponsored by Sunnybrook Health Sciences Centre.

What drugs are being tested in NCT03679468?

Interventions in NCT03679468: Cognitive Rehabilitation, Sham Exercise, Sham Cognitive Rehabilitation, Aerobic Exercise.

What condition does NCT03679468 study?

NCT03679468 studies Multiple Sclerosis, Primary Progressive, Cognitive Impairment.

Is NCT03679468 still recruiting?

NCT03679468 is currently completed. Last updated 8 November 2023.

Last reviewed 2023-11-08 · How we verify

NCT03679468

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation

Completed NA Last updated 8 November 2023

What this trial tests

NA trial testing Cognitive Rehabilitation in Multiple Sclerosis, Primary Progressive in 309 participants. Completed in 3 February 2023.

Timeline

18 March 2019

Primary endpoint
30 October 2022

3 February 2023

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	other
Enrollment	309
Start date	18 March 2019
Primary completion	30 October 2022
Estimated completion	3 February 2023
Sites	1 location across Canada

Drugs / interventions tested

Cognitive Rehabilitation
Sham Exercise
Sham Cognitive Rehabilitation
Aerobic Exercise — full drug profile →

Conditions studied

Multiple Sclerosis, Primary Progressive — all drugs for Multiple Sclerosis, Primary Progressive →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

Adults 25 to 65, any sex, with Multiple Sclerosis, Primary Progressive or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Given that up to 70% of people with secondary progressive MS are cognitively impaired, the search for effective treatments is considered a priority by people living with the disease. This proposal will address the effectiveness of cognitive rehabilitation (CR) and exercise, either alone, or in combination in this regard. A team of MS researchers has been assembled from the USA, Canada, the United Kingdom, Italy, Denmark, Germany and Belgium for this. A total of 360 people with progressive MS will make up the sample. Brain MRIs will be undertaken in a third of the sample before and after the 12 weeks of treatment to document the functional changes that are expected to occur with symptom improvement.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.
Feinstein A, Amato MP, Brichetto G, Chataway J, et al · · 2023 · cited 47× · PMID 37739574 · DOI 10.1016/s1474-4422(23)00280-6
Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx).
Feinstein A, Amato MP, Brichetto G, Chataway J, et al · · 2020 · cited 28× · PMID 32443981 · DOI 10.1186/s12883-020-01772-7
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
Rocca MA, Valsasina P, Romanò F, Tedone N, et al · · 2024 · cited 6× · PMID 38754979 · DOI 10.1136/jnnp-2024-333460
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.
Chen Z, Mao Z, Tang W, Shi Y, et al · · 2025 · cited 4× · PMID 41299782 · DOI 10.1186/s40035-025-00517-1
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
Feinstein A, Amato MP, Brichetto G, Chataway J, et al · · 2022 · cited 4× · PMID 34741240 · DOI 10.1007/s00415-021-10881-3
Prevalence and Associated Clinical Characteristics of Walking-Related Motor, Cognitive, and Fatigability in Progressive Multiple Sclerosis: Baseline Results From the CogEx Study.
Ramari C, D'hooge M, Dalgas U, Feinstein A, et al · · 2024 · cited 3× · PMID 38426484 · DOI 10.1177/15459683241236161
Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
Romanò F, Rocca MA, Pagani E, Amato MP, et al · · 2025 · cited 1× · PMID 40986118 · DOI 10.1007/s00415-025-13382-9
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
Feinstein A, Amato MP, Brichetto G, Chataway J, et al · · 2022 · cited 1× · PMID 35939096 · DOI 10.1007/s00415-022-11295-5

Verify or expand the search:

Other trials of Cognitive Rehabilitation

Trials testing the same drug.

NCT06949696 — Effect of Dual-Task Training and Cognitive Rehabilitation in Individuals With Multiple Sclerosis. · NA · recruiting
NCT06555302 — Cognitive Priming for Stroke Tele-rehabilitation · NA · completed
NCT06511154 — The Effect of Cognitive Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Multiple Sclerosis · NA · recruiting
NCT07160218 — Effects of tDCS and Cognitive Rehabilitation on Cognition and Neural Plasticity in MS Patients · NA · completed
NCT06069882 — Cognitive Rehabilitation for People With Mild-to-moderate Dementia · NA · unknown

Other recruiting trials for Multiple Sclerosis, Primary Progressive

Currently open trials in the same condition.

NCT05359653 — Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy · Phase 1, PHASE2 · recruiting
NCT05204459 — MS-ResearchBiomarkerS · recruiting
NCT04544449 — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary · Phase 3 · active not recruiting
NCT04035005 — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis · Phase 3 · active not recruiting

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03679468 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
Last refreshed: 8 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03679468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing